Special Drug Use-results Surveillance of Scemblix Tablets

Special Drug Use-results Surveillance of Scemblix Tablets (Resistant or Intolerant Chronic Myeloid Leukemia , CABL001A1401)

ClinicalTrials.gov Identifier: NCT05421091

Novartis Reference Number: CABL001A1401

Last Update: Aug 11, 2022

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.

Condition 
Chronic Myeloid Leukemia
Phase 
Not Given
Overall status 
Recruiting
Start date 
Jul 01, 2022
Completion date 
Jul 15, 2028
Gender 
All
Age(s)
99 Years and older (Child, Adult, Older Adult)

Interventions

Other
Asciminib
Prospective observational study. There is no treatment allocation. Patients prescribed with asciminib are eligible to enroll into this study.

Eligibility Criteria

Inclusion Criteria:

patients treated with asciminib in Japan.

Exclusion Criteria:

NA

Study Locations

Japan
Novartis Investigative Site
Recruiting
Toyohashi, 441-8111
Aichi
Japan
Novartis Investigative Site
Recruiting
Matsuyama-city, 790-8524
Ehime
Japan
Novartis Investigative Site
Recruiting
Muroran, 050-0076
Hokkaido
Japan
Novartis Investigative Site
Recruiting
Sapporo, 060-0004
Hokkaido
Japan
Novartis Investigative Site
Recruiting
Kobe-city, 650-0047
Hyogo
Japan
Novartis Investigative Site
Recruiting
Kobe-city,
Hyogo
Japan
Novartis Investigative Site
Recruiting
Kobe, 657-0064
Hyogo
Japan
Novartis Investigative Site
Recruiting
Nishinomiya, 663 8501
Hyogo
Japan
Novartis Investigative Site
Recruiting
Takarazuka, 665-0827
Hyogo
Japan
Novartis Investigative Site
Recruiting
Tsukuba, 300-2622
Ibaraki
Japan
Novartis Investigative Site
Recruiting
Suwa, 392-8510
Nagano
Japan
Novartis Investigative Site
Recruiting
Nagasaki-shi, 852-8511
Nagasaki
Japan
Novartis Investigative Site
Recruiting
Ikoma, 630-0293
Nara
Japan
Novartis Investigative Site
Recruiting
Tenri, 632-8552
Nara
Japan
Novartis Investigative Site
Recruiting
Maniwa, 719-3105
Okayama
Japan
Novartis Investigative Site
Recruiting
Osaka Sayama, 589 8511
Osaka
Japan
Novartis Investigative Site
Recruiting
Osaka-city, 541-8567
Osaka
Japan
Novartis Investigative Site
Recruiting
Osaka-city, 543-8555
Osaka
Japan
Novartis Investigative Site
Recruiting
Nagahama, 526-0831
Shiga
Japan
Novartis Investigative Site
Recruiting
Matsue, 690-8506
Shimane
Japan
Novartis Investigative Site
Recruiting
Wakayama-city, 641-8510
Wakayama
Japan
Novartis Investigative Site
Recruiting
Nara, 630-8305
-
Japan
Novartis Investigative Site
Recruiting
Okayama, 700-8557
-
Japan
Novartis Investigative Site
Recruiting
Osaka, 540-0008
-
Japan
Novartis Investigative Site
Recruiting
Osaka, 542-0081
-
Japan

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]